Lipid Nanoparticles – From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement
Lipid nanoparticles (LNPs) have emerged across the pharmaceutical industry as promising vehicles to deliver a variety of therapeutics. Currently in the spotlight as vital components of the COVID-19 mRNA vaccines, LNPs play a key role in effectively protecting and transporting mRNA to cells. Liposomes, an early version of LNPs, are a versatile nanomedicine delivery platform.
A number of liposomal drugs have been approved and applied to medical practice. Subsequent generations of lipid nanocarriers, such as solid lipid nanoparticles, nanostructured lipid carriers, and cationic lipid–nucleic acid complexes, exhibit more complex architectures and enhanced physical stabilities. With their ability to encapsulate and deliver therapeutics to specific locations within the body and to release their contents at a desired time, LNPs provide a valuable platform for treatment of a variety of diseases. Here, we present a landscape of LNP-related scientific publications, including patents and journal articles, based on analysis of the CAS Content Collection, the largest human-curated collection of published scientific knowledge.
Rising trends are identified, such as nanostructured lipid carriers and solid lipid nanoparticles becoming the preferred platforms for numerous formulations. Recent advancements in LNP formulations as drug delivery platforms, such as antitumor and nucleic acid therapeutics and vaccine delivery systems, are discussed. Challenges and growth opportunities are also evaluated in other areas, such as medical imaging, cosmetics, nutrition, and agrochemicals. This report is intended to serve as a useful resource for those interested in LNP nanotechnologies, their applications, and the global research effort for their development.
Download the full article here: Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement
or continue reading here: Rumiana Tenchov, Robert Bird, Allison E. Curtze, and Qiongqiong Zhou. ACS Nano 2021, Lipid Nanoparticles – From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement, Publication Date: June 28, 2021 https://doi.org/10.1021/acsnano.1c04996
Common Ingredients Used for the Preparation of SLN and NLC
| Lipids | Emulsifiers/coemulsifiers |
|---|---|
| Triglycerides | Lecithin |
| Trimyristin (Dynasan 114) | Poloxamer 188 |
| Tripalmitin (Dynasan 116) | Poloxamer 407 |
| Tristearin (Dynasan 118) | Tyloxapol |
| Mono-, di-, and triglyceride mixtures | Polysorbate 20 |
| Witeposol bases | Polysorbate 60 |
| Glyceryl stearates (Imwitor 900) | Polysorbate 80 |
| Glyceryl behenates (Compritol 888 ATO) | Sodium cholate |
| Glyceryl palmitostearates (Precirol ATO 5) | Sodium glycocholate |
| Waxes | Taurodeoxycholic acid sodium |
| Beeswax | Butanol and Butyric acid |
| Cetyl palmitate | Cetylpyridinium chloride |
| Hard fats | Sodium dodecyl sulfate |
| Stearic acid | Sodium oleate |
| Palmitic acid | Polyvinyl alcohol |
| Behenic acid | Cremophor EL |
| Other lipids | |
| Miglyol 812 | |
| Paraffin |